NCT04412785View on ClinicalTrials.gov

Cyclosporine in Patients With Moderate COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
COVID-19
Interventions
DRUG

Cyclosporine

• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT04412785 - Cyclosporine in Patients With Moderate COVID-19 | Biotech Hunter | Biotech Hunter